📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. (2022)

First Author: Hudert CA

Attributed to: The validation of biomarkers of metabolic efficacy in infant nutrition funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/hep4.1955

PubMed Identifier: 35411667

Publication URI: http://europepmc.org/abstract/MED/35411667

Type: Journal Article/Review

Volume: 6

Parent Publication: Hepatology communications

Issue: 8

ISSN: 2471-254X